Matribhumi Samachar English
San Diego, California–(Newsfile Corp. – June 25, 2025) – Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic conditions, today announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has …
Read More »Thiogenesis Therapeutics to Present at UMDF’s Mitochondrial Medicine 2025 Conference
Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome Spectrum San Diego, California–(Newsfile Corp. – June 20, 2025) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders, today announced that …
Read More »Thiogenesis Announces Grant of Stock Options
San Diego, California–(Newsfile Corp. – June 12, 2025) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to the terms of the Company’s Omnibus Equity …
Read More »Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
San Diego, California–(Newsfile Corp. – February 12, 2025) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its common shares are now trading on the …
Read More »Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
San Diego, California–(Newsfile Corp. – January 27, 2025) – Thiogenesis Therapeutics, and Corp. (TSXV: TTI) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that the European Medicines Agency (“EMA”) has accepted its Clinical …
Read More »